Travere Therapeutics (TVTX) Q2 2024 earnings summary

Executive summary

• Achieved record demand and revenue for FILSPARI in Q2 2024, with net product sales of $27.1M, 521 new patient start forms, and six consecutive quarters of growth, positioning it as foundational therapy for IgA nephropathy.

• Net product sales rose to $52.2M for Q2 2024, up from $29.5M in Q2 2023, driven by FILSPARI growth.

• FILSPARI's addressable patient population is expected to nearly double with anticipated full approval and broader label, supported by strong two-year PROTECT data.

• International expansion is progressing, with CSL Vifor preparing for FILSPARI's European launch and Renalys initiating pivotal studies in Japan.

• Strategic focus remains on rare kidney and metabolic diseases, with FILSPARI and pegtibatinase as key pipeline assets.

Financial highlights

• Total revenue for Q2 2024 was $54.1M, up from $32.2M in Q2 2023, with net product sales of $52.2M.

• Net loss for Q2 2024 was $70.4M ($0.91 per share), improved from $85.6M ($1.13 per share) in Q2 2023; adjusted net loss was $50.1M ($0.65 per share) vs. $60.1M ($0.79 per share) last year.

• Cash, cash equivalents, and marketable securities totaled $325.4M as of June 30, 2024.

• Operating cash use declined by $20M sequentially, with further declines expected in H2 2024 and 2025.

• R&D expenses for Q2 2024 were $54.3M (non-GAAP: $50.6M), down from $66.5M (non-GAAP: $59.5M) in Q2 2023.

Outlook and guidance

• Anticipates full FDA approval and broader label for FILSPARI in early September, expected to expand the addressable patient population from 30,000 to up to 70,000.

• Expects continued growth in FILSPARI sales, contributions from Thiola, and milestone payments from CSL Vifor to support operations into 2028.

• KDIGO guidelines update anticipated soon, likely to include FILSPARI as foundational therapy and broaden treatment targets.

• Pegtibatinase top-line data expected in 2026; FSGS regulatory path update anticipated after Parasol Group's endpoint recommendations.

• Management expects available cash and investments to fund operations beyond the next 12 months.